FDA Investigator Jacqueline A O'shaughnessy, PhD

Jacqueline A O'shaughnessy, PhD has conducted inspections on 77 sites in 2 countries as of 06 Sep 2010. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
77
Last Inspection Date:
06 Sep 2010
Investigator Role:
FDA Investigation Participant
Redica ID:
100000746
Countries of Inspections:
United States of America, Canada
FDA Investigators that have inspected at least one site in common with Jacqueline A O'shaughnessy, PhD:
Albert F Peacock, PhD, Allen F Hall, Ana P Barido, Andrea A Branche, Andrew R Wasko, Annemarie Bodnar, Antoinette L Ravelli, Arindam Dasgupta, PhD, Barbara J Holladay, Barbara Janine Breithaupt, Barbara M Frazier, Brandon L Mariner, Brooke K Higgins, Brunilda Torres, Byungja E Marciante, Candice C Mandera, Candice J Cortes, Carl A Anderson, Carl J Montgomery, Carla C Tuite, Carol Rivera Lopez, PhD, Carol S Sanchez, Catherine Whiteside, PhD, Cathleen A Carr Sharpe, Charles M Kerns, BLT DO, Charles R Bonapace, PhD, Chris J Drabick, Christine M Whitby, CSO, Connie P Rezendes, Courtney N Long, Ct Viswanathan, PhD, Cynthia A Harris, MD, RN, Dana M Klimavicz, David K Glasgow, Dawn L Wydner, Denise M Visco, Investigator, Dhaval H Patel, Dianne H Milazzo, Donald B Mckechnie, Doreen P Gubbay, Dr. Abhijit Raha, PhD, Dr. Gopa Biswas, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Dylan D Yao, MD, PhD, Edward O'shaughnessy, Elise A Murphy, Emest F Bizjak, Erin L Mcfiren, Erin M Mcdowell, Gianine E Tompkins, Gifford Whitehurst, Jr, Grace P Santos, Hector Jcolon Torres, Heika R Bounds, Heika R Tait, Hitesh R Patel, Hugh M Mcclure, II, Huixia Zhang, Iris C Macinnes, Jane M Kreis, Jason M Sluzynski, Jean M Kelahan, Jeanne D Shaffer, Jennifer A Longie Vollom, Jodi M Gatica, John A Kadavil, PhD, John J Welsh, PhD, John Kadavil, PhD, Jonee J Mearns, Judith A Jones, Judith A Paterson, Julian C Hanson, Kalavati Suvarna, PhD, Kara A Scheibner, PhD, Karen M Kondas, Kathryn A Krentz, Kelly Doremus, Kelly I Anderson, Kenneth Nieves, Larry K Austin, Lawrence R Johnson, LCDR Matthew R Mcnew, MPH, REHS/RS, Linda S Leja, Linda Thai, Lisa B Orr, Lisa P Oakes, Lori J Silverstein, LT Melanie M Mayor, USPHS, Lynette P Salisbury, Marcelo O Mangalindan, Jr, Margaret M Annes, Margaret M Sands, Maria Pkelly Doggett, MBA, Martin K Yau, PhD, Melissa B Libby, Melissa J Garcia, Michael F Skelly, PhD, Michael J Nerz, Michael Rosner, Michael Serrano, Mike M Rashti, Mohsen Rajabi Abhari, FDA, Nathaniel R Esaw, Nerizza B Dalena, Nerizza B Guerin, Nilufer M Tampal, PhD, Nina Yang, Patrick D Stone, MS, Raymond L Cheung, Robert Barron, Robert C Steyert, Sam H Haidar, PhD, Samuel H Chan, PharmD, Sarah Forney, Scott B Laufenberg, Sean Y Kassim, PhD, Sherry L Secrist, BLT DO, Srinivas R Chennamaneni, PhD, Sripal R Mada, PhD, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Stephanie T Durso, Steven J Thurber, Sunitha K Rajaram, PhD, Susan F Laska, MS, Tamal K Chakraborti, PhD, Tamika E Allen, RN, Tracy L Taras, PhD, Veronica L Bush, Vlada Matusovsky, Wayne J Meyer, William H Linkroum, William J Muszynski, William L Bargo, Xiaohan Cai, PhD, Xikui Chen (nmi), PhD, Yih Chain Huang, PhD

Jacqueline A O'shaughnessy, PhD's Documents

Publish Date Document Type Title
December, 2005 FDA 483 Response PPD Development, L.P. - Form 483R, 2005-12-22
May, 2006 EIR PPD Development, L.P. - EIR, 2006-05-17
January, 2001 EIR Covance Laboratories, Inc. - EIR, 2001-01-11
October, 2001 EIR Celsis In Vitro Inc. - EIR, 2001-10-12
October, 2004 EIR PPD Development, L.P. - EIR, 2004-10-14
March, 2001 FDA 483 Response Algorithme Pharma Inc. - Form 483R, 2001-03-23
August, 2002 EIR American Histolabs Inc - EIR, 2002-08-22
July, 2000 EIR Covance Laboratories, Inc. - EIR, 2000-07-27
December, 2005 FDA 483 PPD Development, L.P. - Form 483, 2005-12-15
November, 2000 FDA 483 Response Covance Laboratories, Inc. - Form 483R, 2000-11-28
October, 2000 FDA 483 Biovail Contract Research - Form 483, 2000-10-27
August, 2000 EIR Frederick G. Hayden, M.D. - EIR, 2000-08-11
May, 2010 FDA 483 Cetero Research - Form 483, 2010-05-07
November, 2009 EIR Altasciences Preclinical Seattle, LLC - EIR, 2009-11-20
May, 2006 FDA 483 Response PPD Development, L.P. - Form 483R, 2006-06-13
April, 2008 FDA 483 Syneos Health Clinical, Inc. - Form 483, 2008-04-18
April, 2000 FDA 483 Bioanalytical Systems Inc - Form 483, 2000-04-28
June, 2009 EIR Merck & Company, Inc. - EIR, 2009-06-05
March, 2008 FDA 483 PPD Development, L.P. - Form 483, 2008-03-11
May, 2002 EIR PPD Development, L.P. - EIR, 2002-05-17
October, 2004 FDA 483 MDS Pharma Services - Form 483, 2004-09-21
June, 2003 FDA 483 Biovail Contract Research - Form 483, 2003-06-13
December, 2000 EIR Bioanalytical Systems Inc - EIR, 2000-12-19
July, 2004 FDA 483 PPD Development, L.P. - Form 483, 2004-07-21
October, 2000 EIR Biovail Contract Research - EIR, 2000-10-27
September, 2003 EIR PPD Development, L.P. - EIR, 2003-09-05
August, 2000 FDA 483 Response Frederick G. Hayden, M.D. - Form 483R, 2000-08-21
November, 2000 FDA 483 Covance Laboratories, Inc. - Form 483, 2000-11-02
June, 2010 FDA 483 Pfizer Inc. - Form 483, 2010-06-11
November, 2009 FDA 483 Altasciences Preclinical Seattle, LLC - Form 483, 2009-11-20
July, 2000 FDA 483 Response Covance Laboratories, Inc. - Form 483R, 2000-08-25
July, 2004 EIR PPD Development, L.P. - EIR, 2004-07-21
September, 2003 FDA 483 PPD Development, L.P. - Form 483, 2003-09-05
October, 2001 FDA 483 Celsis In Vitro Inc. - Form 483, 2001-10-12
October, 2004 EIR MDS Pharma Services - EIR, 2007-06-15
March, 2009 FDA 483 PPD Development, L.P. - Form 483, 2009-03-06
December, 2005 EIR PPD Development, L.P. - EIR, 2005-12-15
April, 2000 EIR Bioanalytical Systems Inc - EIR, 2000-07-24
July, 2004 FDA 483 Response PPD Development, L.P. - Form 483R, 2004-08-16
March, 2001 FDA 483 Algorithme Pharma Inc. - Form 483, 2001-03-09
March, 2001 EIR Algorithme Pharma Inc. - EIR, 2001-04-02
August, 2000 FDA 483 Frederick G. Hayden, M.D. - Form 483, 2000-08-11
May, 2002 FDA 483 PPD Development, L.P. - Form 483, 2002-05-17
July, 2000 FDA 483 Covance Laboratories, Inc. - Form 483, 2000-07-27
October, 2010 FDA 483 Human Genome Sciences Inc - Form 483, 2010-09-24
October, 2000 FDA 483 Response Biovail Contract Research - Form 483R, 2000-11-09

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more